To determine the presence of a red-HMGB1 that can complex with CXCL12 in the tumor microenvironment, a mass spectrometry protocol that allows an unambiguous differentiation between the HMGB1 redox isoforms was developed. The gene discussed is CXCL12; the disease is neoplasm.